All In Biotech

Drug Trial Radar · NCT06300320

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

A Randomized, Open-label, Multicenter Phase II Clinical Trial of Rovadicitinib in the Treatment of Third-line and Subsequent Moderate to Severe Chronic Graft-versus-host Disease (cGVHD).

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

May 7, 2024

Primary completion

Nov 2027

Study completion May 2029

Sponsor

Sponsor type
Industry
First posted
Mar 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease

Conditions

  • Chronic Graft Versus Host Disease

Interventions

  • TQ05105 tabletsDrug

    Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) at 24 weeksTime frame: Up to 24 weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • The 940th hospital of joint logistics support force of Chinese people's liberation army

    Lanzhou, Gansu, China · Not yet recruiting

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Not yet recruiting

  • Tai'an Central Hospital

    Taian, Shangdong, China · Not yet recruiting

  • Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shannxi, China · Not yet recruiting

  • Hematology Hospital of the Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The Affiliated People's Hospital of Ningbo University

    Ningbo, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.